This is a study for naïve patients (never been treated) with HIV-1. It compares the safety and efficacy of a new combination tablet of D/C/F/TAF (darunavir/cobistat/emtricitibine/tenofovir alafenamide) to Prezcobix (Darunavir/cobistat) + Truvada (emtricitibine/tenofovir). Participants will be followed for 2 years on study. The study will pay for all related medications, labs and office visits.
Who may be Eligible
Eligible participants include: 1) HIV-1 adults (age 18 or older), 2) have never been on therapy for HIV, 3) HIV viral load greater than 1000 and a CD4 count greater than 50, 4) Normal maintenance labs, 5) Must agree to study defined birth control methods and not donate eggs or sperm during the study, 6) Not have acute hepatitis in past 30 days, 7) No hepatitis C (untreated) or Hepatitis B;, 8) No cancer in past 5 years, 9) No other condition or medical history that may interfere with the protocol or participants ability to compete the study as defined by the protocol or study doctor, 10) Cannot be pregnant, breastfeeding, planning to become pregnant or father a child up to 90 days after study, 11) Other criteria to be discussed at the screening/education visit.